Every Country, Every Family: Time to Act for Group B Streptococcal Disease Worldwide | Zendy

Joy E. Lawn | Zendy; Jaya Chandna | Zendy; Proma Paul | Zendy; Mark Jit | Zendy; Caroline Trotter | Zendy; Philipp Lambach | Zendy; Ajoke Sobanjo Ter-Meulen | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Every Country, Every Family: Time to Act for Group B Streptococcal Disease Worldwide

Author(s) -

Joy E. Lawn,

Jaya Chandna,

Proma Paul,

Mark Jit,

Caroline Trotter,

Philipp Lambach,

Ajoke Sobanjo Ter-Meulen

Publication year - 2021

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciab859

Subject(s) - medicine , inclusion (mineral) , streptococcus agalactiae , streptococcus , disease , call to action , group b , family medicine , intensive care medicine , business , marketing , gender studies , pathology , sociology , biology , bacteria , genetics

The global burden of Group B Streptococcus (GBS) was estimated for 2015 prompting inclusion of GBS as a priority in the Global Meningitis Roadmap. New estimates for the year 2020 and a WHO report analysing the full value of GBS maternal vaccines has been launched to advance evidence based decision making for multiple stakeholders. In this first of a 10-article supplement, we discuss the following (1) gaps in evidence and action, (2) new evidence in this supplement, and (3) what actions can be taken now and key research gaps ahead. We call for investment in the research pipeline, notably description, development, and delivery, in order to accelerate progress and address the large burden of GBS for every family in every country.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research